NCT00113529View on ClinicalTrials.gov

Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

September 30, 2007

Study Completion Date

October 31, 2008

Conditions
Carcinoma, Renal Cell
Interventions
DRUG

Gefitinib + Sunitinib

Until disease progression or unacceptable toxicity.

Trial Locations (3)

10021

Pfizer Investigational Site, New York

48109

Pfizer Investigational Site, Ann Arbor

19111-2497

Pfizer Investigational Site, Philadelphia

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY